


[VIEW IN FRAME](#)

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

aidsline
NATIONAL LIBRARY OF MEDICINE



DONATE NOW
SECURE DONATIONS
BY GROUNDSPRING.org



**PRINT THIS
ARTICLE**

Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.

Blood. 1988 Nov;72(5):1805-16. Unique Identifier : AIDSLINE MED/89027118

Waldmann TA; Goldman CK; Bongiovanni KF; Sharrow SO; Davey MP; Cease KB; Greenberg SJ; Longo DL; Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.

Abstract: Human T-cell lymphotropic virus I (HTLV-I)-induced adult T-cell leukemia (ATL) cells constitutively express interleukin-2 (IL-2) receptors identified by the anti-Tac monoclonal antibody (MoAb), whereas normal resting cells do not. This observation provided the scientific basis for a trial of intravenous anti-Tac in the treatment of nine patients with ATL. The patients did not suffer untoward reactions and did not have a reduction in the normal formed elements of the blood, and only one of the nine produced antibodies to the anti-Tac MoAb. Three patients had transient mixed, partial, or complete remissions lasting from 1 to more than 8 months after anti-Tac therapy, as assessed by routine hematologic tests, immunofluorescence analysis of circulating cells, and molecular genetic analysis of HTLV-I provirus integration and of the T-cell receptor gene rearrangement. The precise mechanism of the antitumor effects is unclear; however, the use of a MoAb that prevents the interaction of IL-2 with its receptor on ATL cells provides a rational approach for the treatment of this malignancy.

Keywords: Adult Antibodies, Monoclonal/*THERAPEUTIC USE Female Gene Rearrangement, beta-Chain T-Cell Antigen Receptor Human Immunotherapy Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/BLOOD/GENETICS/*THERAPY Male Middle Age Receptors, Interleukin-2/*IMMUNOLOGY T-Lymphocytes/IMMUNOLOGY/PHYSIOLOGY JOURNAL ARTICLE


890228
M8920104

Copyright © 1989 - **National Library of Medicine**. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is made possible through unrestricted grants from **Boehringer Ingelheim, iMetrikus, Inc.**, the **National Library of Medicine**, and **donations** from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. comments@aegis.org



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Bio	
Search	PubMed	<input type="checkbox"/> for							Go	Clear
		Limits	Preview/Index	History	Clipboard	Details				
Display		Abstract	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	

Entrez PubMed

☐ 1: Blood. 1988 Nov;72(5):1805-16.[Related Articles, Links](#)

PubMed Services

Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.

Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB, Greenberg SJ, Longo DL.

Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.

Related Resources


Human T-cell lymphotropic virus I (HTLV-I)-induced adult T-cell leukemia (ATL) cells constitutively express interleukin-2 (IL-2) receptors identified by the anti-Tac monoclonal antibody (MoAb), whereas normal resting cells do not. This observation provided the scientific basis for a trial of intravenous anti-Tac in the treatment of nine patients with ATL. The patients did not suffer untoward reactions and did not have a reduction in the normal formed elements of the blood, and only one of the nine produced antibodies to the anti-Tac MoAb. Three patients had transient mixed, partial, or complete remissions lasting from 1 to more than 8 months after anti-Tac therapy, as assessed by routine hematologic tests, immunofluorescence analysis of circulating cells, and molecular genetic analysis of HTLV-I provirus integration and of the T-cell receptor gene rearrangement. The precise mechanism of the antitumor effects is unclear; however, the use of a MoAb that prevents the interaction of IL-2 with its receptor on ATL cells provides a rational approach for the treatment of this malignancy.

PMID: 2846094 [PubMed - indexed for MEDLINE]

Display	Abstract	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	<input type="checkbox"/>
---------	----------	--------------------------	----------	--------------------------	------	--------------------------	---------	------	--------------------------

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
[Freedom of Information Act](#) | [Disclaimer](#)

Apr 6 2004 10:25:18



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search PubMed	<input type="checkbox"/> for Limits	Preview/Index		History	Clipboard	Go Clear			
Display		Citation	<input type="checkbox"/> Show: 20	<input type="checkbox"/> Sort	Send to		Text		

Entrez PubMed

☐ 1: Blood. 1993 Sep 15;82(6):1701-12.[Related Articles, Links](#)

PubMed Services

The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia.

Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, Roessler E, Horak ID, Zaknoen S, Kasten-Sportes C, et al.

Metabolism Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Related Resources

Adult T-cell leukemia (ATL) is a malignancy of mature lymphocytes caused by the retrovirus human T-cell lymphotropic virus-I (HTLV-I). It is an aggressive leukemia with an overall mortality rate of 50% within 5 months; no conventional chemotherapy regimen appears successful in inducing long-term disease-free survival in ATL patients. However, ATL cells constitutively express high-affinity interleukin-2 receptors (IL-2Rs) identified by the anti-Tac monoclonal antibody, whereas normal resting cells do not. To exploit this difference in receptor expression, we administered anti-Tac intravenously (IV) to 19 patients with ATL. In general the patients did not suffer untoward reactions, and in 18 of 19 cases did not have a reduction in normal formed elements of the blood. Seven patients developed remissions that were mixed (1 patient), partial (4 patients), or complete (2 patients), with partial and complete remissions lasting from 9 weeks to more than 3 years as assessed by routine hematologic tests, immunofluorescence analysis, and molecular genetic analysis of T-cell receptor gene rearrangements and of HTLV-I proviral integration. Furthermore, remission was associated with a return to normal serum calcium levels and an improvement of liver function tests. Remission was also associated in some cases with an amelioration of the profound immunodeficiency state that characterizes ATL. Thus the use of a monoclonal antibody that blocks the interaction of IL-2 with its receptor expressed on ATL cells provides a rational approach for treatment of this aggressive malignancy.

MeSH Terms:

- Adult
- Antibodies, Monoclonal/therapeutic use*
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Blotting, Southern
- Female
- Follow-Up Studies
- Gene Rearrangement, T-Lymphocyte
- Human
- Human T-lymphotropic virus 1/genetics

- Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/drug therapy
- Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/genetics
- Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/immunology*
- Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/therapy*
- Male
- Middle Aged
- Receptors, Interleukin-2/immunology*
- Restriction Mapping
- Virus Integration

Substances:

- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Receptors, Interleukin-2

PMID: 8400227 [PubMed - indexed for MEDLINE]

Display	Citation	<input type="checkbox"/>	Show: 20	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Send to	Text	<input type="checkbox"/>
---------	----------	--------------------------	----------	--------------------------	------	--------------------------	---------	------	--------------------------

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

Apr 6 2004 10:25:18

blood**TIPS
for Better Browsing**[HOME](#) [HELP](#) [FEEDBACK](#) [SUBSCRIPTIONS](#) [ARCHIVE](#) [SEARCH](#) [TABLE OF CONTENTS](#)Institution: [U S PATENT TRADEMARK OFFC](#) [Sign In as Individual](#)**QUICK SEARCH:**Author: Key:
 Years: Vol:

Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2

TA Waldmann, CK Goldman, KF Bongiovanni, SO Sharrow, MP Davey, KB Cease, SJ Greenberg and DL Longo

- ▶ [Order Full Text via Infotrieve](#)
- ▶ [Email this article to a friend](#)
- ▶ [Similar articles found in:](#)
[Blood Online](#)
[PubMed](#)
- ▶ [PubMed Citation](#)
- ▶ [This Article has been cited by:](#)
[other online articles](#)
- ▶ [Search PubMed for articles by:](#)
[Waldmann, T. A. || Longo, D. L.](#)
- ▶ [Alert me when:](#)
[new articles cite this article](#)
- ▶ [Download to Citation Manager](#)


Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.

Human T-cell lymphotropic virus I (HTLV-I)-induced adult T-cell leukemia (ATL) cells constitutively express interleukin-2 (IL-2) receptors identified by the anti-Tac monoclonal antibody (MoAb), whereas normal resting cells do not. This observation provided the scientific basis for a trial of intravenous anti-Tac in the treatment of nine patients with ATL. The patients did not suffer untoward reactions and did not have a reduction in the normal formed elements of the blood, and only one of the nine produced antibodies to the anti-Tac MoAb. Three patients had transient mixed, partial, or complete remissions lasting from 1 to more than 8 months after anti-Tac therapy, as assessed by routine hematologic tests, immunofluorescence analysis of circulating cells, and molecular genetic analysis of HTLV-I provirus integration and of the T-cell receptor gene rearrangement. The precise mechanism of the antitumor effects is unclear; however, the use of a MoAb that prevents the interaction of IL-2 with its receptor on ATL cells provides a rational approach for the treatment of this malignancy.

Volume 72, Issue 5, pp. 1805-1816, 11/01/1988


Copyright © 1988 by The American Society of Hematology

This article has been cited by other articles:



The NEW ENGLAND JOURNAL of MEDICINE [HOME](#)

F. M. Foss, S. L. Aquino, and J. A. Ferry
Case 10-2003 - A 72-Year-Old Man with Rapidly Progressive Leukemia, Rash, and Multiorgan Failure
 N. Engl. J. Med., March 27, 2003; 348(13): 1267 - 1275.
[\[Full Text\]](#) [\[PDF\]](#)



The NEW ENGLAND JOURNAL of MEDICINE

HOME

P. S. Gill, W. Harrington, M. H. Kaplan, R. C. Ribeiro, J. M. Bennett, H. A. Liebman, M. Bernstein-Singer, B. M. Espina, L. Cabral, S. Allen, S. Kornblau, M. C. Pike, and A. M. Levine

Treatment of Adult T-Cell Leukemia-Lymphoma with a Combination of Interferon Alfa and Zidovudine

N. Engl. J. Med., June 29, 1995; 332(26): 1744 - 1748.

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)



Cancer Research

HOME

K. E. Phillips, B. Herring, L. A. Wilson, M. S. Rickford, M. Zhang, C. K. Goldman, J. Y. Tso, and T. A. Waldmann

IL-2R $\{\alpha\}$ -Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2R $\{\alpha\}$ Interaction

Cancer Res., December 1, 2000; 60(24): 6977 - 6984.

[\[Abstract\]](#) [\[Full Text\]](#)



Proceedings of the National Academy of Sciences

HOME

P. S. Gill, Y. C. Tsai, A. P. Rao, C. H. Spruck III, T. Zheng, W. A. Harrington Jr., T. Cheung, B. Nathwani, and P. A. Jones

Evidence for multiclonality in multicentric Kaposi's sarcoma

PNAS, July 7, 1998; 95(14): 8257 - 8261.

[\[Abstract\]](#) [\[Full Text\]](#) [\[PDF\]](#)

HOME

HELP

FEEDBACK

SUBSCRIPTIONS

ARCHIVE

SEARCH

TABLE OF CONTENTS

AGRYLIN[®]
(anagrelide hydrochloride)
CAPSULES OF 0.5 MG AND 1 MG

Blood Online is sponsored by an
unrestricted grant from Shire

Copyright © 1988 by American Society of Hematology.